NCT00548262 - This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

CandidemiaInvasive Candidiasis

Interventions

DRUG

Anidulafungin

All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.

DRUG

Voriconazole

Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if \<40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if \<40 kg body weight).

Trial Locations (13)

37320

Pfizer Investigational Site, León

44280

Pfizer Investigational Site, Guadalajara

78240

Pfizer Investigational Site, San Luis Potosí City

8380456

Pfizer Investigational Site, Independencia

70710-905

Pfizer Investigational Site, Brasília

80060-900

Pfizer Investigational Site, Curitiba

21941-913

Pfizer Investigational Site, Rio de Janeiro

90020-090

Pfizer Investigational Site, Porto Alegre

90110-270

Pfizer Investigational Site, Porto Alegre

15090-000

Pfizer Investigational Site, São José do Rio Preto

0000

Pfizer Investigational Site, Bogota DC

Pfizer Investigational Site, Santiago de Cali

Unknown

Pfizer Investigational Site, Panama City